R&D strategy

Ipsen’s R&D is recognized for its unique expertise and leadership in peptides and toxins. Its research strategy is guided by the principle of service to patients to deliver therapeutic solutions for unmet medical needs.

Bloc image R&D


Ipsen’s Research & Development comprises both new molecule development programs and lifecycle management programs for our existing products.

2 innovative scientific platforms

Focused on peptides and toxins, our R&D teams are concentrating and developing their expertise on these two platforms, with the objective of increasing their understanding of both basic sciences and clinical aspects. In these fields, Ipsen has entered into agreements with highly specialized companies and is strengthening its partnership policy through agreements with major research institutes and medical centers of excellence, on a global scale.


3 internationally renowned R&D centers

Paris-Saclay in France, Oxford in the United Kingdom and Cambridge in the United States: with an open innovation model in mind, Ipsen has placed its three R&D centers at the heart of three internationally reputed scientific hubs. It has also put its three R&D centers in contact with leading academic research centers, cutting edge medical centers and technological companies.

Clinical trials

The research teams at Ipsen develop innovative medicines by working closely with both doctors and patients. A global network of healthcare professionals help Ipsen test new treatments and ensure their efficacy and safety by conducting studies called clinical trials. Find out more about these studies in the new "clinical trials" section of our website.

View of clinical trials

Scientific affairs

Ipsen’s Scientific Affairs department manages R&D’s public and private collaborations. The partnerships that we develop with major research institutes and medical centers of excellence especially allow us to test the relevance of our research concepts.